New product launches for Ocular Implant Market 2019? Novartis AG, Pfizer Inc., Staar Surgical, Johnson & Johnson Services, Inc., Bausch & Lomb Incorporated., Morcher GmbH, OSD Medical GmbH, Ophtec BV

In July 2018, Alcon launched its intraocular lens (IOL) portfolio including, Clareon AutonoMe IOL and delivery system, designed to provide easy and intuitive control during cataract surgery, at the Alcon-hosted Synergeyes clinical symposium in Sydney. AutonoMe is the first and only automated, disposable, preloaded IOL delivery system preloaded with the Clareon IOL, and it is automated with CO2-powered delivery mechanism. Moreover, in June 2018, Molteno Ophthalmic launched its Molteno3 S-Series glaucoma implants at the 24th Greek Glaucoma.

Moreover, increasing prevalence of corneal diseases is expected to increase the demand for ocular implants. For instance, according to the World Health Organization (WHO), corneal blindness is one of the major causes of visual deficiency after cataract, glaucoma and age-related macular degeneration (AMD) and 4th cause of blindness globally (5.1%). Moreover, according WHO, cornea diseases affects around 30 million people and around two million new cases of corneal dysfunction diagnose each year.

Free Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2699

Increasing product launches for different types ocular implants that are widely used in ophthalmic surgery to correct ophthalmic deformities is expected to drive global ocular implant market growth. For instance, in February 2019, EyePoint Pharmaceuticals, Inc. launched its YUTIQ in the U.S. YUTIQ is three-year intravitreal micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The product was approved by U.S. FDA in October 2018.

Moreover, increasing prevalence of ocular dysfunction and disorder is expected to drive growth of the global ocular implant market. For instance, in January 2019, according to Glaucoma research foundation, currently, there are over 3 million people in the U.S. that have been diagnosed with glaucoma. The National Eye Institute projects that this number will be increased by 58% and expected to reach 4.2 million by 2030.

Moreover, in March 2019, Implandata Ophthalmic Products GmbH (Implandata) received CE marking for its next generation EYEMATE-IO 1.1 implantable micro-sensor. The novel product will help eye surgeons to place the permanent implantable eye pressure sensor in conjunction with cataract surgery through significantly smaller incisions. In April 2019, company launched EYEMATE-IO 1.1 in Europe.

Furthermore, in June 2018, HumanOptics received U.S. Food and Drug Administration (FDA) approval for its CustomFlex Artificial Iris, first stand-alone prosthetic iris. CustomFlex Artificial Iris (HumanOptics) is a flexible silicone device indicated for adults and children with congenital aniridia or iris defects due to albinism, traumatic injury, or surgical removal.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2699

However, product recall for ocular implants is expected to hinder the global ocular implant market growth. For instance, in October 2018, Drug Controller General of India (DCGI) issued a product recall notice to Allergan India Private Limited for its Ozurdex Intravitreal Implant due to detection of silicone particle in it.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.